SMO and skin basal cell carcinoma: A recent study has shown that the inhibition of the Hh pathway in BCC patients treated with vismodegib or sonidegib (SMO inhibitors) resulted in an increased MHC-I expression in tumor cells associated with a high number of CD4 and CD8 T cells infiltrating the tumors [55].